Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Abbott Settlement With DOJ Highlights Feds’ Anti-Fraud Efforts

Executive Summary

Abbott will pay $5.47 million to resolve allegations that it paid physicians for teaching assignments, speaking engagements and conferences with the expectation that they would in return facilitate product purchases at their hospitals.

You may also be interested in...



C.R. Bard Pays $48 Million To Settle Brachytherapy False Claims Act Allegations

The settlement addresses allegations by the Justice Department that the company provided kickbacks to Medicare customers and physicians from 1998 to 2006 to purchase brachytherapy seeds used to treat prostate cancer.

Medicare/Medicaid Prosecutions: Does More Money for Fraud Activities Translate Into More Mega-Settlements?

From expanding health care coverage to collecting fees from miscreants, the lead story at HHS took a quick and sharp turn with the unveiling of the President's budget for fiscal 2011. HHS is setting high return standards for its fraud activities: $1.5 in net returns to the government for every dollar spent. Practically, that may drive HHS to press big pharma for big settlements.

FDA Rounds Up Biliary Stent Makers On Off-label Promotion

FDA gathered biliary stent manufacturers to discuss how to prevent off-label marketing for peripheral vascular disease while it clarifies the regulatory pathway for vascular stents

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT035716

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel